BRIEF-Skye Reports Positive Cbeyond Phase 2A Extension Interim Study Results For Nimacimab

Reuters
Feb 02
BRIEF-Skye Reports Positive Cbeyond Phase 2A Extension Interim Study Results For Nimacimab

Feb 2 (Reuters) - Skye Bioscience Inc SKYE.O:

  • SKYE REPORTS POSITIVE CBEYOND PHASE 2A EXTENSION INTERIM STUDY RESULTS FOR NIMACIMAB IN COMBINATION WITH SEMAGLUTIDE

  • SKYE BIOSCIENCE INC - 22.3% WEIGHT LOSS AT 52 WEEKS WITH NIMACIMAB + SEMAGLUTIDE (2.4 MG) COMBINATION

  • SKYE BIOSCIENCE INC - FULL TOPLINE REPORTING OF CBEYOND PHASE 2A DATA EXPECTED Q3 2026

Source text: ID:nGNXc9xN7x

Further company coverage: SKYE.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10